Posted by Michael Wonder on 07 Jan 2025
Nuvation Bio receives approval from China’s National Medical Products Administration for taletrectinib for patients with advanced ROS1 positive non-small cell lung cancer
6 January 2025 - Taletrectinib will be marketed in China by Innovent Biologics.
Nuvation Bio today announced that China’s National Medical Products Administration has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer who either have or have not been previously treated with ROS1 tyrosine kinase inhibitors.
